Mechanism
A target receptor and expected biological response explain a hypothesis, not a guaranteed outcome.
Weight Management · Research
Understand metabolic research.
A home for GLP-1, GIP and glucagon science, with context, restraint and attention to the true level of evidence.
Editorial scope. This section explains concepts and publications. It does not recommend treatment, provide doses or replace advice from a qualified healthcare professional.
Essential reading
Two strong places to begin
Start with receptors and evidence levels, then examine the current state of retatrutide research.
GLP-1, GIP and glucagon: how to read receptor science
Receptors explain a research strategy. On their own, they do not predict an outcome for an individual.
Retatrutide: what research shows, and what it cannot yet establish
A structured reading of the clinical programme, current limitations and the exact meaning of investigational.
How to assess a peptide claim: six focused questions
Six questions reveal whether a claim goes further than the evidence supporting it.
Reading map
What credible research keeps separate.
A promising molecule is not a conclusion. Interpretation depends on the model, comparator, duration and regulatory status.
Clinical evidence
Randomised human research estimates effects and risks in a defined population, with important limitations.
Current status
A phase 3 programme or positive paper does not mean a product is approved or appropriate for individual use.
The useful boundary
Inform without turning research into a promise.
BEL prioritises primary sources and trial registries, names the study type and dates every update. Future developments can be added here with visible references and without treatment instructions.